Popular Trials
Efzofitimod for Scleroderma-Related Lung Disease
This trial is testing a new drug called efzofitimod to see if it can help people with a lung disease linked to systemic sclerosis. The goal is to find out if the drug can improve their breathing and skin health.
Immunomodulator
Privigen for Systemic Sclerosis
This trial is testing an antibody solution given through an IV in patients with scleroderma who haven't improved with standard treatments. The goal is to see if this treatment can help their immune system work better and reduce disease symptoms. The study will last for several months and involve a small group of patients.
Monoclonal Antibodies
TEPEZZA for Systemic Sclerosis
This trial is testing TEPEZZA, a medicine that blocks a protein causing inflammation and scarring, in patients with a skin condition called diffuse cutaneous systemic sclerosis. The study will see if TEPEZZA is safe and effective when given over several months. The goal is to find out if it can help reduce symptoms in these patients.
Cannabinoid Receptor Agonist
EHP-101 for Systemic Sclerosis
This trial is testing a new drug called EHP-101 to see if it is safe and effective for adults with a severe skin disease called diffuse cutaneous Systemic Sclerosis. The study will check how the drug moves through the body, how well patients can tolerate it, and if it helps improve their condition.
Popular Filters
Trials for SSc Patients
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Procedure
Extracorporeal Photopheresis for Systemic Sclerosis
This trial is testing a treatment called Extracorporeal Photopheresis for patients with a severe form of scleroderma. The treatment involves taking blood out, treating it with light and a drug, and then putting it back in. The goal is to see if this can safely reduce skin thickening and improve symptoms. Extracorporeal photopheresis (ECP) has been used for over 30 years, initially for cutaneous T-cell lymphoma and later for other diseases including scleroderma.
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Trials for Systemic Scleroderma Patients
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Alkylating agents
Stem Cell Transplant for Scleroderma
This trial tests a treatment for systemic scleroderma involving stem cell collection, high-dose chemotherapy, and immune suppression, followed by returning the patient's own stem cells and using a maintenance drug to prevent disease recurrence. The treatment has shown a satisfactory risk-benefit ratio in earlier studies.
Alkylating agents
TBI + Cyclophosphamide and Stem Cell Transplant for Scleroderma
This trial is testing the side effects and feasibility of a new way to give total body radiation therapy (IMRT) with the chemotherapy drug cyclophosphamide before stem cell transplant to treat severe systemic sclerosis.
Skin involvement for Systemic Sclerosis
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms. With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them. Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.
BI 685509 for Systemic Sclerosis
This trial is testing a medicine called Avenciguat to see if it helps adults with a condition called scleroderma, which affects the skin and internal organs. Participants take the medicine for several months. The study checks if the medicine improves lung function and other symptoms.
Trials With No Placebo
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Procedure
Extracorporeal Photopheresis for Systemic Sclerosis
This trial is testing a treatment called Extracorporeal Photopheresis for patients with a severe form of scleroderma. The treatment involves taking blood out, treating it with light and a drug, and then putting it back in. The goal is to see if this can safely reduce skin thickening and improve symptoms. Extracorporeal photopheresis (ECP) has been used for over 30 years, initially for cutaneous T-cell lymphoma and later for other diseases including scleroderma.
Alkylating agents
Stem Cell Transplant for Scleroderma
This trial tests a treatment for systemic scleroderma involving stem cell collection, high-dose chemotherapy, and immune suppression, followed by returning the patient's own stem cells and using a maintenance drug to prevent disease recurrence. The treatment has shown a satisfactory risk-benefit ratio in earlier studies.
View More Related Trials
Frequently Asked Questions
Introduction to
What are the top hospitals conducting undefined research?
The quest for medical advancements and improved treatments is an ongoing journey, extending beyond specific conditions to encompass a wide range of health concerns. In this pursuit, several top hospitals are leading the way in clinical trials for undefined conditions. Massachusetts General Hospital in Boston stands out with four active trials focused on these elusive ailments. Known for their commitment to innovative research, this hospital's dedication shines through as they strive to unravel the mysteries surrounding unidentified diseases.
On the West Coast, Pacific Arthritis Care Center brings its expertise to bear on these enigmatic conditions as well. Located in Los Angeles, this center conducts four active clinical trials aimed at shedding light on undefined illnesses that continue to challenge the medical community.
Heading further east, Johns Hopkins University in Baltimore has also devoted significant resources toward understanding and treating unknown disorders. With three ongoing clinical trials dedicated to undefined conditions, this renowned institution showcases its commitment to pushing boundaries and seeking answers where there are none.
In Houston, The University of Texas Health Science Center is making substantial contributions by conducting two active clinical trials related to undisclosed diseases. Through rigorous scientific investigation and collaboration with experts from various fields, they aim to make significant breakthroughs that can positively impact patients' lives.
Across the Atlantic Ocean lies St. Joseph's Health Care Rheumatology Clinic in London—a notable player when it comes to tackling poorly understood illnesses head-on. This clinic actively engages in two mysterious condition-focused clinical trials while providing hope and support for patients grappling with unidentified health challenges.
As we navigate through uncharted territories within healthcare, these leading hospitals serve as beacons of progress—channeling their knowledge and expertise into finding solutions even when faced with uncertainty. The determination of researchers within these institutions reinforces their unwavering commitment towards uncovering answers that will ultimately improve countless lives impacted by undetermined conditions worldwide
Which are the best cities for undefined clinical trials?
When it comes to undefined clinical trials, several cities emerge as prominent hubs for research. Los Angeles, California leads the way with 16 ongoing trials investigating treatments like MK-2225, HZN-825 QD, and MT-7117. Houston, Texas follows closely behind with 10 active trials focusing on interventions such as Peripheral Blood Stem Cell Transplantation and Transcutaneous Electrical Acustimulation (TEA). Additionally, Boston Massachusetts and Baltimore Maryland both offer opportunities for participation in 10 and 8 studies respectively. Finally, Cleveland Ohio presents promising options with its 7 current trials exploring treatments like TEPEZZA and efzofitimod 450 mg. These cities serve as important centers for cutting-edge research that contributes to the advancement of medical knowledge and potential breakthroughs in healthcare.
Which are the top treatments for undefined being explored in clinical trials?
Currently, there are several top treatments for undefined conditions being investigated in clinical trials. These include:
- Daratumumab: Being tested in six active trials and has a total of 134 breast cancer trials since 2012.
- Belantamab mafodotin: Under examination in four ongoing trials with a history of 26 breast cancer trials since its introduction in 2018.
- Lenalidomide: Engaged in three active breast cancer studies and has been part of 280 clinical trials across various conditions since its debut in 2003.
With each trial, researchers come closer to uncovering potential breakthroughs that may benefit patients facing undefined health challenges.
What are the most recent clinical trials for undefined?
Several exciting clinical trials have recently emerged, offering potential breakthroughs in the realm of undefined conditions. One promising study focuses on efzofitimod 450 mg, a Phase 2 trial that became available on September 1st, 2023. Additionally, Mycophenolate mofetil is being investigated as a treatment option through another Phase 2 trial for this condition. A Phase 3 trial involving Anifrolumab administered subcutaneously on a weekly basis also holds promise for patients with undefined conditions and became available on July 13th, 2023. These trials aim to provide valuable insights into potential treatments and improve patient outcomes in the face of this enigmatic ailment.
What undefined clinical trials were recently completed?
I apologize, but I cannot provide a specific answer to the question as it asks for "undefined" clinical trials. Could you please provide more information or specify which clinical trials you are referring to? That way, I can offer a clear and accurate response tailored to your query.